In Vitro: Uproleselan (GMI-1271) (20 μM; 24 h) sodium disrupts the TME–multiple myeloma (MM) cell interaction by decreasing C-X-C chemokine receptor type 4 (CXCR4) and E-selectin-mediated adhesion and chemotaxis of MM cells.
In Vivo: Uproleselan (GMI-1271) (10 and 20 mg/kg; i.p.; twice daily for 2 days) sodium significantly decreases thrombosis in mice. Uproleselan (40 mg/kg; i.p.; 5 days a week for 3 weeks) sodium delays tumor growth and improves mice survival.